JP2017535246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535246A5 JP2017535246A5 JP2017512808A JP2017512808A JP2017535246A5 JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5 JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 114
- 239000000611 antibody drug conjugate Substances 0.000 claims 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 239000002254 cytotoxic agent Substances 0.000 claims 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 claims 6
- 102100032239 Melanotransferrin Human genes 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 201000000849 skin cancer Diseases 0.000 claims 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 4
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 4
- 210000005102 tumor initiating cell Anatomy 0.000 claims 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 108010027164 Amanitins Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101100261262 Homo sapiens MELTF gene Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical group CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 2
- 229930188854 dolastatin Natural products 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 2
- 229960005501 duocarmycin Drugs 0.000 claims 2
- 229930184221 duocarmycin Natural products 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- -1 maytansinoid Natural products 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 229940125645 monoclonal antibody drug Drugs 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000004611 cancer cell death Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000004237 preparative chromatography Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046610P | 2014-09-05 | 2014-09-05 | |
| US62/046,610 | 2014-09-05 | ||
| US201562203836P | 2015-08-11 | 2015-08-11 | |
| US62/203,836 | 2015-08-11 | ||
| PCT/US2015/048659 WO2016037119A1 (en) | 2014-09-05 | 2015-09-04 | Novel anti-mfi2 antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535246A JP2017535246A (ja) | 2017-11-30 |
| JP2017535246A5 true JP2017535246A5 (Direct) | 2019-04-25 |
Family
ID=55440418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512808A Pending JP2017535246A (ja) | 2014-09-05 | 2015-09-04 | 新規の抗ｍｆｉ２抗体および使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10428156B2 (Direct) |
| EP (1) | EP3189079A4 (Direct) |
| JP (1) | JP2017535246A (Direct) |
| KR (1) | KR20170045351A (Direct) |
| CN (1) | CN107001454A (Direct) |
| AU (1) | AU2015311743A1 (Direct) |
| BR (1) | BR112017004444A2 (Direct) |
| CA (1) | CA2959705A1 (Direct) |
| CL (2) | CL2017000506A1 (Direct) |
| CO (1) | CO2017003005A2 (Direct) |
| CR (1) | CR20170117A (Direct) |
| DO (1) | DOP2017000052A (Direct) |
| EA (1) | EA201790529A1 (Direct) |
| IL (1) | IL250825A0 (Direct) |
| MA (1) | MA40612A (Direct) |
| MX (1) | MX2017002862A (Direct) |
| PE (1) | PE20170776A1 (Direct) |
| PH (1) | PH12017500406A1 (Direct) |
| SG (1) | SG11201701650PA (Direct) |
| TW (1) | TW201617368A (Direct) |
| WO (1) | WO2016037119A1 (Direct) |
| ZA (1) | ZA201701674B (Direct) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20190353A1 (es) * | 2016-04-15 | 2019-03-07 | Macrogenics Inc | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos |
| EP3760641A4 (en) * | 2018-02-27 | 2021-11-24 | Eisai R&D Management Co., Ltd. | MONOCLONAL ANTIBODIES AGAINST APOA4, IMMUNOASSAY AND KIT FOR MEASUREMENT |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| WO2020021556A1 (en) * | 2018-07-26 | 2020-01-30 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions targeting gabra2 and methods for diagnosis and treatment of cancer |
| SG11202106672SA (en) * | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Antibody drug conjugates (adc) containing saponin |
| CN109709340B (zh) * | 2018-12-29 | 2022-02-11 | 江苏众红生物工程创药研究院有限公司 | 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用 |
| WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
| US11617798B2 (en) * | 2019-02-05 | 2023-04-04 | Seagen Inc. | Anti-CD228 antibodies and antibody-drug conjugates |
| JP7597784B2 (ja) * | 2019-07-11 | 2024-12-10 | タヴォテック バイオセラピューティクス （ホン コン） リミテッド | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤 |
| GB201913594D0 (en) * | 2019-09-20 | 2019-11-06 | Univ Birmingham | Epigenetic profiling method |
| CN111909933B (zh) * | 2020-06-29 | 2021-07-02 | 浙江大学 | 靶向细胞表面抗原mfi2蛋白的核酸适配体及应用 |
| AU2021320739A1 (en) * | 2020-08-04 | 2023-02-23 | Seagen Inc. | Anti-CD228 antibodies and antibody-drug conjugates |
| WO2022187050A1 (en) * | 2021-03-01 | 2022-09-09 | BioLegend, Inc. | Anti-cd117 agents and compositions and methods for making and using the same |
| CN116925216B (zh) * | 2022-04-11 | 2024-09-24 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
| TW202426501A (zh) * | 2022-09-21 | 2024-07-01 | 美商思進公司 | 結合cd228之抗體 |
| WO2025025731A1 (zh) * | 2023-07-28 | 2025-02-06 | 山东博安生物技术股份有限公司 | 一种适用于免疫组化检测cd228的诊断抗体 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| USRE38008E1 (en) | 1986-10-09 | 2003-02-25 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| PT938320E (pt) | 1996-03-26 | 2010-09-22 | Michael S Kopreski | Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| WO1999037779A1 (en) | 1998-01-22 | 1999-07-29 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
| NZ510493A (en) | 1998-08-27 | 2003-11-28 | Spirogen Ltd | Pyrrolobenzodiazepin-5-one derivatives for treating viral, bacterial and protozoal infections |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP4414023B2 (ja) * | 1999-08-05 | 2010-02-10 | オリエンタル酵母工業株式会社 | 関節炎関連メラノトランスフェリンの測定方法および試薬 |
| AU785028C (en) | 2000-02-08 | 2007-05-03 | Bioasis Advanced Technologies Inc. | Compositions and methods for screening therapeutic agents |
| KR20020007432A (ko) * | 2000-07-13 | 2002-01-29 | 박현석 | 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약 |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| EP1256354A1 (en) | 2001-05-11 | 2002-11-13 | Schering Corporation | Methods for treating cancer |
| TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| DK2364996T3 (en) | 2002-09-27 | 2017-02-06 | Xencor Inc | Optimized Fc variants and methods for their formation |
| US7608429B2 (en) | 2002-10-31 | 2009-10-27 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1419786A1 (en) | 2002-11-13 | 2004-05-19 | Bracco Imaging S.p.A. | Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US7619068B2 (en) | 2003-05-09 | 2009-11-17 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| EP1626735B1 (en) | 2003-05-09 | 2014-11-19 | Transfert Plus | Compound for treating cancer caused by cells expressing melanotransferrin at their surface |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| SI2270010T1 (sl) | 2004-03-01 | 2012-05-31 | Spirogen Ltd | hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| AU2006239851B2 (en) | 2005-04-26 | 2011-06-16 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| JP2009538629A (ja) | 2006-05-30 | 2009-11-12 | ジェネンテック・インコーポレーテッド | 抗体およびイムノコンジュゲートとこれらの使用方法 |
| CA2658003A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| US20080220448A1 (en) | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
| PL2063907T3 (pl) | 2006-09-07 | 2018-06-29 | Frankel | Sposoby i kompozycje oparte na koniugatach toksyny błoniczej z interleukiną-3 |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| AU2008296386A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of IGF-1R |
| US20100226925A1 (en) | 2007-09-14 | 2010-09-09 | Amgen Inc. | Homogeneous Antibody Populations |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| JP2011509675A (ja) | 2008-01-18 | 2011-03-31 | メディミューン，エルエルシー | 部位特異的コンジュゲーションのためのシステイン操作抗体 |
| US20100162416A1 (en) | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| AU2011217794B2 (en) | 2010-02-21 | 2015-01-29 | Bayer Healthcare Llc | Method for activation and conjugation of biomolecules |
| US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
| EP2558127B1 (en) * | 2010-04-15 | 2022-01-19 | Seagen Inc. | Targeted pyrrolobenzodiazepine conjugates |
| JP5875083B2 (ja) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| RS52983B (sr) | 2010-04-15 | 2014-02-28 | Spirogen Sárl | Pirolobenzodiazepini i njihovi konjugati |
| CN119552249A (zh) | 2010-06-08 | 2025-03-04 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| WO2012031280A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| JPWO2012036094A1 (ja) | 2010-09-17 | 2014-02-03 | 独立行政法人産業技術総合研究所 | 肺癌鑑別マーカー |
| JP6014596B2 (ja) | 2010-11-09 | 2016-10-25 | メディミューン，エルエルシー | 均一コンジュゲーションのための抗体足場 |
| EP2648751A4 (en) | 2010-12-09 | 2015-04-15 | Bayer Healthcare Llc | DIMERE MOLECULAR COMPLEXES WITH FREE CYSTEIN RESTANTS AND CONJUGATES THEREOF |
| HRP20180147T1 (hr) | 2011-03-02 | 2018-02-23 | Roche Glycart Ag | Cea protutijela |
| WO2013006706A1 (en) * | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
| PL2739649T3 (pl) | 2011-08-05 | 2018-03-30 | Bioasis Technologies Inc. | Fragmenty p97 o aktywności transferowej |
| KR20140084191A (ko) | 2011-10-19 | 2014-07-04 | 쎄러테크놀로지스 인코포레이티드 | 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도 |
| KR20110136776A (ko) * | 2011-12-12 | 2011-12-21 | 경북대학교 산학협력단 | 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법 |
| HRP20201004T1 (hr) | 2011-12-20 | 2020-10-16 | Medimmune, Llc | Modificirani polipeptidi za skelete bispecifičnog protutijela |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| JP6401060B2 (ja) * | 2012-02-24 | 2018-10-03 | アッヴィ・ステムセントルクス・エル・エル・シー | 抗ｓｅｚ６抗体及び使用方法 |
| BR112014022228A2 (pt) * | 2012-03-08 | 2017-07-11 | Halozyme Inc | anticorpos anti-epidérmicos de receptor de fator de crescimento condicionalmente ativo e métodos de uso dos mesmos |
| JP6189415B2 (ja) | 2012-04-02 | 2017-08-30 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| NZ705040A (en) * | 2012-07-20 | 2017-07-28 | Cleave Biosciences Inc | Fused pyrimidines as inhibitors of p97 complex |
| JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| LT2906248T (lt) | 2012-10-12 | 2019-02-11 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
| SI2766048T1 (sl) | 2012-10-12 | 2015-03-31 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| WO2014124316A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| ME03394B (me) | 2013-02-22 | 2020-01-20 | Medimmune Ltd | Antidllз-antitelo-pbd konjugati i nihovа upotreba |
| WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| KR20160018579A (ko) | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| US9944931B2 (en) | 2013-06-10 | 2018-04-17 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| EP3024456A4 (en) | 2013-07-26 | 2017-04-12 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| US10464997B2 (en) | 2014-02-11 | 2019-11-05 | Seattle Genetics, Inc. | Selective reduction of proteins |
| EA201691683A1 (ru) | 2014-02-21 | 2017-04-28 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме |
| US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
-
2015
- 2015-09-03 TW TW104129184A patent/TW201617368A/zh unknown
- 2015-09-04 MA MA040612A patent/MA40612A/fr unknown
- 2015-09-04 CA CA2959705A patent/CA2959705A1/en not_active Abandoned
- 2015-09-04 EP EP15837897.6A patent/EP3189079A4/en not_active Withdrawn
- 2015-09-04 US US15/508,836 patent/US10428156B2/en not_active Expired - Fee Related
- 2015-09-04 MX MX2017002862A patent/MX2017002862A/es unknown
- 2015-09-04 AU AU2015311743A patent/AU2015311743A1/en not_active Abandoned
- 2015-09-04 KR KR1020177009300A patent/KR20170045351A/ko not_active Withdrawn
- 2015-09-04 EA EA201790529A patent/EA201790529A1/ru unknown
- 2015-09-04 CR CR20170117A patent/CR20170117A/es unknown
- 2015-09-04 WO PCT/US2015/048659 patent/WO2016037119A1/en not_active Ceased
- 2015-09-04 CN CN201580060426.9A patent/CN107001454A/zh active Pending
- 2015-09-04 BR BR112017004444-7A patent/BR112017004444A2/en not_active Application Discontinuation
- 2015-09-04 SG SG11201701650PA patent/SG11201701650PA/en unknown
- 2015-09-04 JP JP2017512808A patent/JP2017535246A/ja active Pending
- 2015-09-04 PE PE2017000403A patent/PE20170776A1/es unknown
-
2017
- 2017-02-27 IL IL250825A patent/IL250825A0/en unknown
- 2017-03-02 DO DO2017000052A patent/DOP2017000052A/es unknown
- 2017-03-03 PH PH12017500406A patent/PH12017500406A1/en unknown
- 2017-03-03 CL CL2017000506A patent/CL2017000506A1/es unknown
- 2017-03-08 ZA ZA2017/01674A patent/ZA201701674B/en unknown
- 2017-03-28 CO CONC2017/0003005A patent/CO2017003005A2/es unknown
-
2018
- 2018-06-22 CL CL2018001722A patent/CL2018001722A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535246A5 (Direct) | ||
| US9353182B2 (en) | Anti-DLL3 antibodies | |
| ES2763548T3 (es) | Anticuerpos anti-TIM3 y procedimientos de uso | |
| JP2018127469A5 (Direct) | ||
| JP2016531915A5 (Direct) | ||
| JP2016531914A5 (Direct) | ||
| JP7657213B2 (ja) | 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法 | |
| JP2019532056A5 (Direct) | ||
| KR20160070191A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| US20190201542A1 (en) | Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition | |
| JP2018529656A (ja) | 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法 | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| JP2016536020A5 (Direct) | ||
| CN110494448B (zh) | 包含抗-ly75抗体的医药组合 | |
| KR20160047567A (ko) | 조작된 항-dll3 접합체 및 사용 방법 | |
| KR20180088445A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| JP2015509948A5 (Direct) | ||
| JP2020502271A (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| ES3007557T3 (en) | Anti-edb antibodies and antibody-drug conjugates | |
| KR20170045351A (ko) | 신규한 항-mfi2 항체 및 사용 방법 | |
| JP7578289B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| AU2016355206A1 (en) | Novel anti-EMR2 antibodies and methods of use | |
| JP2019511199A (ja) | 新規の抗ｕｐｋ１ｂ抗体及び使用方法 | |
| AU2017261369A1 (en) | Novel anti-TNFRSF21 antibodies and methods of use | |
| JPWO2020143749A5 (Direct) |